High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus

Lupus

Volumn 17, Issue 11, 2008, Pages 981-987

  Juarez Rojas J G ^a   Medina Urrutia, A X ^a   Posadas Sanchez R ^a   Jorge Galarza, E ^a   Mendoza Perez E ^a   Caracas Portilla, N ^a   Cardoso Saldana G ^a   Munoz Gallegos G ^a   Posadas Romero, Carlos ^a,b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b NONE   (Mexico)

Author keywords

Cardiovascular disease; High density lipoproteins; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD;

ADULT; FEMALE; HUMANS; LIPOPROTEINS, HDL; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 61549139332     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308093072     Document Type: Article

References (39)

1. Wajed J Ahmad Y Durrington PN Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43: 7-12.
2. Jimenez S Garcia-Criado MA Tassies D. et al Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44: 756-761.
3. Posadas-Romero C Torres-Tamayo M Zamora-González J. et al High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 160-165.
4. Tso TK Huang WN. Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: Relation to insulin resistance. J Rheumatol 2007; 34: 726-730.
5. McMahon M Grossman J FitzGerald J. et al Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-2549.
6. Kontush A Chapman MJ. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.
7. Barter P Kastelein J Nunn A Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168: 195-211.
8. Kontush A Chantepie S Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888.
9. Williams PT Krauss RM Nichols AV Vranizan KM Wood PD. Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 1990; 31: 1131-1139.
10. Perez-Mendez O Torres-Tamayo M Posadas-Romero C. et al Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chim Acta 2007; 376: 17-22.
11. Hansel B Giral P Nobecourt E. et al Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-4971.
12. Garvey WT Kwon S Zheng D. et al Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462.
13. Kontush A de Faria EC Chantepie S Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182: 277-285.
14. Calabresi L Gomaraschi M Villa B Omoboni L Dmitrieff C Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 656-661.
15. Brites FD Bonavita CD De Geitere C. et al Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000; 152: 181-192.
16. Asztalos BF Collins D Cupples LA. et al Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-2191.
17. 2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694.
18. Tan EM Cohen AS Fries JF. et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
19. Guzman J Cardiel MH Arce-Salinas A Sanchez-Guerrero J Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
20. DeLong DM DeLong ER Wood PD Lippel K Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-2377.
21. Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Perusse M Pascot A Despres JP Couillard C Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001; 42: 1331-1334.
23. Blanche PJ Gong EL Forte TM Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419.
24. Chapman MJ Goldstein S Lagrange D Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981; 22: 339-358.
25. Sniderman AD Scantlebury T Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-459.
26. Panarotto D Remillard P Bouffard L Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84-92.
27. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995; 6: 153-160.
28. Asztalos BF Roheim PS Milani RL. et al Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-2676.
29. Asztalos BF Cupples LA Demissie S. et al High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187.
30. Assmann G Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341.
31. Navab M Ananthramaiah GM Reddy ST. et al The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1007.
32. Steinberg D Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-2111.
33. Ohta T Saku K Takata K Nakamura R Ikeda Y Matsuda I. Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol 1995; 15: 956-962.
34. Ashby DT Rye KA Clay MA Vadas MA Gamble JR Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1450-1455.
35. Michel P Eggert W Albrecht-Nebe H Grune T. Increased lipid peroxidation in children with autoimmune diseases. Acta Paediatr 1997; 86: 609-612.
36. Ames PR Alves J Murat I Isenberg DA Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38: 529-534.
37. Arita Y Kihara S Ouchi N. et al Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
38. Kumada M Kihara S Sumitsuji S. et al Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
39. Morgan J Carey C Lincoff A Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365.